Cipla Limited on Thursday announced that the United States Food and Drug Administration (USFDA) has classified its inspection at Medispray Laboratories’ manufacturing facility in Kundaim, Goa as Voluntary Action Indicated (VAI).
The inspection was conducted between January 14–20, 2025, and the company received the VAI classification via email on April 11, 2025, which was subsequently shared with Cipla on April 17. The company clarified that the disclosure is not material but is being made as a matter of good governance.
Medispray Laboratories Private Limited is a wholly owned subsidiary of Cipla. A VAI classification indicates that although objectionable conditions were found during inspection, the USFDA does not plan to take any enforcement action, and the facility can continue to operate normally while corrective actions may be voluntarily undertaken.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
